阿贝西利治疗激素受体阳性乳腺癌的临床研究进展

Clinical research progress of abemaciclib in treatment of hormone receptorpositive breast cancer

目前全球有4款获批治疗乳腺癌的细胞周期蛋白依赖性激酶(CDK)4/6抑制剂,分别是哌柏西利、瑞博西利、阿贝西利和达尔西利。其中,阿贝西利是继哌柏西利和瑞博西利之后第3个进入市场的CDK4/6抑制剂,可联合芳香化酶抑制剂(AI)或他莫昔芬作为激素受体阳性(HR^(+))、人表皮生长因子受体2阴性(HER2^(-))早期高危乳腺癌成人患者的辅助治疗,还可联合氟维司群或AI治疗HR^(+)/HER2^(-)局部晚期或转移性乳腺癌。就阿贝西利治疗激素受体阳性乳腺癌的临床研究进展作以综述,以期为临床治疗提供参考。

At present,there are four cyclin-dependent kinase 4/6 inhibitors approved for the treatment of breast cancer in the world,namely:Palbociclib,Ribociclib,Aabemaciclib and Dalpiciclib.Abemaciclib is the third CDK4/6 inhibitor to enter the market after Palbociclib and Ribociclib.It can be combined with aromatase inhibitors or tamoxifen as adjuvant therapy for adult patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative(HR^(+)/HER2^(−))early high-risk breast cancer,and can also be combined with fulvestrant or AI in the treatment of HR^(+)/HER2^(−) locally advanced or metastatic breast cancer.This article reviews the clinical research progress of abemaciclib in the treatment of hormone receptor positive breast cancer,in order to provide reference for clinical treatment.